Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Operating Cash Flow
Cash generated by the company's core business operations during the period.
Aura Biosciences, Inc.NASDAQ: AURA
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $29.89M (cash outflow) rose 28.0% year over year, ahead of the +16.0% change in trailing-twelve-month operating cash flow. Sequentially, it rose 46.0% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +28.0% holds above the trailing-twelve-month pace of +16.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (84.74M) USD
- Year-over-year change
- -6.2%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (84.74M) | -6.2% |
| FY2024 | 2024-12-31 | (79.81M) | -25.0% |
| FY2023 | 2023-12-31 | (63.85M) | -16.9% |
| FY2022 | 2022-12-31 | (54.6M) | -68.5% |
| FY2021 | 2021-12-31 | (32.41M) | — |
Operating Cash Flow vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +16.0% is the 8th highest of 11, against a peer median of +20.3%.
- Over three fiscal years its annual growth of +15.8% compares with a peer median of +30.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $267.54M USD | +80.6% | +54.6% | 3513.3% | |
| LTM Sep 2026 | $229.03M USD | +23.8% | +88.1% | — | |
| LTM Mar 2026 | $228.9M USD | +26.8% | +42.6% | 360.5% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $97.43M USD | +63.6% | +25.2% | 1363.7% |
| LTM Mar 2026 | $91.28M USD | +16.0% | +15.8% | — | |
| LTM Mar 2026 | $73.64M USD | +46.6% | +19.8% | — | |
| LTM Mar 2026 | $69.96M USD | +0.5% | -2.3% | 44.5% | |
| FY2025 | $64.13M USD | -534.4% | +52.4% | 987.0% | |
| LTM Mar 2026 | CHF 62.18M CHF | +16.7% | +35.4% | 12337.0% | |
| LTM Mar 2026 | $59.4M USD | +16.7% | -1.8% | 1330.4% | |
| LTM Mar 2026 | $47.05M USD | -26.5% | -2.9% | 14121.8% | |
| Peer median (excluding AURA) | — | +20.3% | +30.3% | 1347.0% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| Deferred Income Tax | 14K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.31M | 6.41M | 8.77M | 11.72M | 14.32M |
| Change in Working Capital | (315K) | (3.1M) | 4.44M | (2.64M) | 5.97M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.05M | 340K | (1.04M) | 482K | (846K) |
| Other Working Capital | (1.37M) | (3.44M) | 5.48M | (3.12M) | 6.82M |
| Other Non-Cash Items | 4K | (325K) | (1.95M) | (3.19M) | 32K |
| Operating Cash Flow | (32.41M) | (54.6M) | (63.85M) | (79.81M) | (84.74M) |
| Capital Expenditures | (2.13M) | (1.09M) | (709K) | (1.25M) | (447K) |
| Acquisitions (Net) | 0 | 66.78K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (119.78M) | (233.65M) | (59.11M) | (83.96M) |
| Sales of Investments | 0 | 53.01M | 120.4M | 129.18M | 120M |
| Other Investing Activities | 0 | (66.78K) | 0 | 0 | 0 |
| Investing Cash Flow | (2.13M) | (67.87M) | (113.96M) | 68.82M | 35.6M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 78.7M | 8.55M | 3.17M | 1.6M | 77.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 334K | 430K | 1.5M | 0 | 0 |
| Financing Cash Flow | 166.26M | 95.63M | 97.29M | 1.6M | 77.16M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (186K) |
| Net Change in Cash | 131.72M | (26.84M) | (80.52M) | (9.39M) | 27.82M |
| Free Cash Flow | (34.54M) | (55.7M) | (64.56M) | (81.06M) | (85.19M) |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.